Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia

References

• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–2393.
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99(1):4–13.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120(5):960–969.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol 2010;47(3):258–265.
   PubMed Web of Science ®Google Scholar
• Di Buduo CA, Currao M, Pecci A, Kaplan DL, Balduini CL, Balduini A. Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica 2016;101(12):1479–1488.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363(20):1889–1899.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371(9610):395–403.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355(16):1672–1681.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357(22):2237–2247.
   PubMed Web of Science ®Google Scholar
• Catala-Lopez F, Corrales I, De La Fuente-Honrubia C, Gonzalez-Bermejo D, Martin-Serrano G, Montero D, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: an updated systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc). 2015;145 (12):511–9.
   Web of Science ®Google Scholar
• Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010;8(6):1372–1382.
   PubMed Web of Science ®Google Scholar
• Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol 2010;47(3):289–298.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161(3):411–423.
   PubMed Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121(3):537–545.
   PubMed Web of Science ®Google Scholar
• Karpatkin S. Heterogeneity of human platelets. II. Functional Evidence Suggestive of Young and Old Platelets. J Clin Invest. 1969;48(6):1083–1087.
   PubMed Web of Science ®Google Scholar
• Sewify EM, Sayed D, Abdel Aal RF, Ahmad HM, Abdou MA. Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res 2013;131(2):e59–63.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013;161(5):706–714.
   PubMed Web of Science ®Google Scholar
• Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010;95(7):1167–1175.
   PubMed Web of Science ®Google Scholar
• Severinsen MT, Engebjerg MC, Farkas DK, Jensen AO, Norgaard M, Zhao S, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2010;152 (3):360–2.
   Web of Science ®Google Scholar
• Norgaard M, Cetin K, Maegbaek ML, Kristensen NR, Ghanima W, Bahmanyar S, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2015;174 (4):639–42.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 2014;12(8):1266–1273.
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4(2):249–264.
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
   PubMedGoogle Scholar
• Rodeghiero F. Is ITP a thrombophilic disorder?. Am J Hematol 2016;91(1):39–45.
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sorensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 2010;8(6):1413–1416.
   PubMed Web of Science ®Google Scholar
• Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003;50(3):172–175.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Lee SY, Barsam S, Miller A, Sandset PM, Bussel JB. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol. 2012;158 (6):811–4.
   PubMed Web of Science ®Google Scholar
• Alvarez Roman MT, Fernandez Bello I, Arias-Salgado EG, Rivas Pollmar MI, Jimenez Yuste V, Martin Salces M, et al. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thromb Haemost 2014;112(1):65–72.
   PubMed Web of Science ®Google Scholar
• Alvarez-Roman MT, Fernandez-Bello I, Jimenez-Yuste V, Martin-Salces M, Arias-Salgado EG, Rivas Pollmar MI, et al. Procoagulant profile in patients with immune thrombocytopenia. Br J Haematol 2016;175(5):925–934.
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012; 119 (17):4066–72.
   PubMed Web of Science ®Google Scholar
• Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013;109(4):676–683.
   PubMed Web of Science ®Google Scholar
• Cerletti C, De Gaetano G, Lorenzet R. Platelet- leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk. Mediterr J Hematol Infect Dis 2010;2(3):e2010023.
   PubMedGoogle Scholar
• Del Conde I, Nabi F, Tonda R, Thiagarajan P, Lopez JA, Kleiman NS. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol 2005;25(5):1065–1070.
   PubMed Web of Science ®Google Scholar
• Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 2000;97(25):13835–13840.
   PubMed Web of Science ®Google Scholar
• Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101(7):2661–2666.
   PubMed Web of Science ®Google Scholar
• Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112(7):2703–2708.
   PubMed Web of Science ®Google Scholar
• Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 2007;53(7):1235–1243.
   PubMed Web of Science ®Google Scholar
• Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008;22(4):187–194.
   PubMed Web of Science ®Google Scholar
• Moulis G, Audemard-Verger A, Arnaud L, Luxembourger C, Montastruc F, Gaman AM, et al. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. Autoimmun Rev 2016;15(3):203–209.
   PubMed Web of Science ®Google Scholar